U.S. Patent Litigations
PACER
Case No(s):
U.S. Patent Nos.
8,563,698 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,829,165 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,859,741 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,913 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,914 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,883,983 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,889,834 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.; Amgen Manufacturing Limited LLC; Amgen USA, Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480; 20-1074
Supreme Court Appeal(s)
18-127; 21-757
Status
District Court Determination that Patents Valid and Infringed; Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding for New Trial on Written Description and Enablement; Petition for Rehearing En Banc Denied; Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled; Federal Circuit Appeal Affirmed, Request for Panel and En Banc Rehearing Denied; Supreme Court Affirmed
BPCIA
N
U.S. Patent Nos.
8,871,913 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,914 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480; 20-1074
Supreme Court Appeal(s)
18-127
Status
Consolidated with 1:14-cv-01317 (D. Del.); District Court Determination that Patents Valid and Infringed; Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding for New Trial on Written Description and Enablement in Lead Case (1:14-cv-01317; Fed. Cir. 2017-1480); Petition for Rehearing En Banc Denied; Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled; Federal Circuit Appeal Affirmed, Request for Panel and En Banc Rehearing Denied
BPCIA
N
U.S. Patent Nos.
8,883,983 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480; 20-1074
Supreme Court Appeal(s)
18-127
Status
Consolidated with 1:14-cv-01317 (D. Del.); District Court Determination that Patents Valid and Infringed; Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding for New Trial on Written Description and Enablement in Lead Case (1:14-cv-01317; Fed. Cir. 2017-1480); Petition for Rehearing En Banc Denied; Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled; Federal Circuit Appeal Affirmed, Request for Panel and En Banc Rehearing Denied
BPCIA
N
U.S. Patent Nos.
8,889,834 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))
Plaintiffs
Amgen Inc.
Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC
Federal Circuit Appeal(s)
17-1480; 20-1074
Supreme Court Appeal(s)
18-127
Status
Consolidated with 1:14-cv-01317 (D. Del.); District Court Determination that Patents Valid and Infringed; Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding for New Trial on Written Description and Enablement in Lead Case (1:14-cv-01317; Fed. Cir. 2017-1480); Petition for Rehearing En Banc Denied; Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled; Federal Circuit Appeal Affirmed, Request for Panel and En Banc Rehearing Denied
BPCIA
N
U.S. Patent Nos.
7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen)
Plaintiffs
Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis US LLC
Defendants
City of Hope; Genentech, Inc.
Status
Dismissed
BPCIA
N